Figure 4B exhibited the overall survival (OS) analysis results of ADIPOR1/2 across cancers. The higher expression of ADIPOR1 was correlated with ACC and LGG, but was correlated with better OS in KIRC and SARC. The higher expression of ADIPOR2 was correlated with worse OS in LUAD, MESO, and PAAD, but was correlated with better OS in KIRC. Figure 4C showed the results of disease free survival (DFS) analysis. Here, ADIPOR2 is linked to pancreatic adenocarcinoma.